Insider Selling: Zimmer Biomet (NYSE:ZBH) SVP Sells 2,650 Shares of Stock

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president owned 10,224 shares in the company, valued at approximately $967,803.84. This represents a 20.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Zimmer Biomet Trading Up 0.2%

Shares of ZBH stock traded up $0.16 on Monday, hitting $93.36. 1,955,739 shares of the stock traded hands, compared to its average volume of 2,280,309. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. Zimmer Biomet Holdings, Inc. has a twelve month low of $84.59 and a twelve month high of $114.44. The firm’s 50-day moving average price is $92.40 and its two-hundred day moving average price is $95.11. The stock has a market capitalization of $18.27 billion, a PE ratio of 26.37, a PEG ratio of 1.90 and a beta of 0.58.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. The company had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. Zimmer Biomet’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s payout ratio is presently 27.12%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. TD Cowen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Monday, January 26th. Evercore upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $94.00 to $120.00 in a report on Monday, January 5th. William Blair began coverage on Zimmer Biomet in a research report on Friday, February 20th. They set a “market perform” rating for the company. Wells Fargo & Company upped their target price on shares of Zimmer Biomet from $93.00 to $98.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 11th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and an average price target of $106.20.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ZBH. Dodge & Cox increased its stake in Zimmer Biomet by 1.3% during the 4th quarter. Dodge & Cox now owns 23,506,849 shares of the medical equipment provider’s stock worth $2,113,736,000 after buying an additional 290,676 shares during the period. Vanguard Group Inc. boosted its position in Zimmer Biomet by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 23,483,741 shares of the medical equipment provider’s stock valued at $2,111,658,000 after buying an additional 192,517 shares during the period. State Street Corp grew its stake in shares of Zimmer Biomet by 2.3% in the fourth quarter. State Street Corp now owns 8,826,974 shares of the medical equipment provider’s stock worth $795,814,000 after acquiring an additional 195,214 shares in the last quarter. Capital International Investors grew its stake in shares of Zimmer Biomet by 11.5% in the third quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock worth $743,749,000 after acquiring an additional 778,467 shares in the last quarter. Finally, Franklin Resources Inc. increased its position in shares of Zimmer Biomet by 43.2% during the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock worth $601,204,000 after acquiring an additional 2,017,857 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.